Avances en el manejo del cáncer de pulmón


  • L.M Montuenga Solid Tumors Program. Center of Applied Medical Research (CIMA). University of Navarra. Pamplona, Spain.
  • J.J. Zulueta Servicio de Neumología. Clínica Universidad de Navarra. Pamplona, España.




Sin resumen disponible.


Los datos de descargas todavía no están disponibles.


RICO M, FLAMARIQUE ANDUEZA S, MARTÍN MARTÍNEZ A, RODRÍGUEZ MENDIZÁBAL MA, ROSAS GUTIÉRREZ L, MARTÍNEZ LÓPEZ E. How to integrate stereotactic body radiation therapy and hypofractionation in the management of stage III lung cancer in the age of immunotherapy. An Sist Sanit Navar 2020. https://doi.org/10.23938/ASSN.0855

SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7-30. https://doi.org/10.3322/caac.21590

NYBERG K. Stunning progress achieved in lung cancer treatment over the last decade. IASLC Lung Cancer News 2020. https://www.lungcancernews.org/2020/04/16/stunning-progress-achieved-in-lung-cancer-treatment-over-the-last-decade/

HUANG P-W, CHANG JW-C. Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomed J 2019; 42: 299-306. https://doi.org/10.1016/j.bj.2019.09.002

BRASSART-PASCO S, DALSTEIN V, BRASSART B, DEWOLF M, CLAVEL C, OUDART J-B. Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns. Pharmacogenomics 2020; 21: 705-720. https://doi.org/10.2217/pgs-2020-0021

UPRETY D, MANDREKAR SJ, WIGLE D, RODEN AC, ADJEI AA. Neoadjuvant immunotherapy for non-small cell lung cancer: current concepts and future approaches. J Thorac Oncol 2020; 15: 1281-1297. https://doi.org/10.1016/j.jtho.2020.05.020

GILL J, CETNAR JP, PRASAD V. A timeline of immune checkpoint inhibitor approvals in small cell lung cancer. Trends Cancer 2020; 29. https://doi.org/10.1016/j.trecan.2020.05.014

RAGAVAN M, DAS M. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy. Curr Treat Options Oncol 2020; 21: 64. https://doi.org/10.1007/s11864-020-00762-8

ROSSI G, RUSSO A, TAGLIAMENTO M, TUZI A, NIGRO O, VALLOME G et al. Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. Cancers 2020; 12. https://doi.org/10.3390/cancers12051125

SORIA J-C, OHE Y, VANSTEENKISTE J, REUNGWETWATTANA T, CHEWASKULYONG B, LEE KH et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378: 113-125. https://doi.org/10.1056/NEJMoa1713137

RAMALINGAM SS, VANSTEENKISTE J, PLANCHARD D, CHO BC, GRAY JE, OHE Y et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020; 382: 41-50. https://doi.org/10.1056/nejmoa1913662

SOLOMON BJ, BESSE B, BAUER TM, FELIP E, SOO RA, CAMIDGE DR et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol 2018; 19: 1654-1667. https://doi.org/10.1016/s1470-2045(18)30649-1

SHAW AT, SOLOMON BJ, CHIARI R, RIELY GJ, BESSE B, SOO RA et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol 2019; 20: 1691-1701. https://doi.org/10.1016/s1470-2045(19)30655-2

DRILON A, SIENA S, OU S-HI, PATEL M, AHN MJ, LEE J et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov 2017; 7: 400-409. https://doi.org/10.3410/f.727294853.793541382

DRILON A, SIENA S, DZIADZIUSZKO R, BARLESI F, KREBS MG, SHAW AT et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020; 21: 261-270. https://doi.org/10.1016/S1470-2045(19)30690-4.

DURUISSEAUX M. Lorlatinib: a new treatment option for ROS1-positive lung cancer. Lancet Oncol 2019; 20: 1622-1623. https://doi.org/10.1016/s1470-2045(19)30716-8

LASSEN U. Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours. Lancet Oncol 2020; 21: 193-194. https://doi.org/10.1016/s1470-2045(19)30789-2

ROSKOSKI RJ. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacol Res 2020; 152: 104609. https://doi.org/10.1016/j.phrs.2019.104609

HAN Y. Current status of proton therapy techniques for lung cancer. Radiat Oncol J 2019; 37: 232-248. https://doi.org/10.3857/roj.2019.00633

VIDETIC GMM, DONINGTON J, GIULIANI M, HEINZERLING J, KARAS TZ, KELSEY CR et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 2017; 7: 295-301. https://doi.org/10.1016/j.prro.2017.04.014

GUCKENBERGER M, ANDRATSCHKE N, DIECKMANN K, HOOGEMAN MS, HOYER M, HURKMANS C et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol 2017; 124 : 11-17. https://doi.org/10.1016/j.radonc.2017.05.012

ANTONIA SJ, VILLEGAS A, DANIEL D, VICENTE D, MURAKAMI S, HUI R et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379: 2342-2350. https://doi.org/10.1056/NEJMoa1809697

PAZ-ARES L, SPIRA A, RABEN D, PLANCHARD D, CHO BC, ÖZGÜROĞLU M et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol 2020; 31: 798-806. https://doi.org/10.1016/j.annonc.2020.03.287

GRAY JE, VILLEGAS A, DANIEL D, VICENTE D, MURAKAMI S, HUI R et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage iii NSCLC - Update from PACIFIC. J Thorac Oncol 2020; 15: 288-293. https://doi.org/10.1016/j.jtho.2019.10.002

YAMADA T, UCHINO J, CHIHARA Y, SHIMAMOTO T, IWASAKU M, TAMIYA N et al. Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study). Ther Adv Med Oncol 2020; 12. https://doi.org/10.1177/1758835920927841

WALLE T, MARTINEZ MONGE R, CERWENKA A, AJONA D, MELERO I, LECANDA F. Radiation effects on antitumor immune responses: current perspectives and challenges. Ther Adv Med Oncol 2018; 10.. https://doi.org/10.1177/1758834017742575

RODRIGUEZ-RUIZ ME, VITALE I, HARRINGTON KJ, MELERO I, GALLUZZI L. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nat Immunol 2020; 21: 120-134. https://doi.org/10.1038/s41590-019-0561-4

RODRÍGUEZ-RUIZ ME, VANPOUILLE-BOX C, MELERO I, FORMENTI SC, DEMARIA S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol 2018; 39: 644-655. https://doi.org/10.1016/j.it.2018.06.001

RODRIGUEZ-RUIZ ME, RODRIGUEZ I, LEAMAN O, LÓPEZ-CAMPOS F, MONTERO A, CONDE AJ et al. Immune mechanisms mediating abscopal effects in radioimmunotherapy. Pharmacol Ther 2019; 196: 195-203. https://doi.org/10.1016/j.pharmthera.2018.12.002

BERFIELD KS, FARJAH F, MULLIGAN MS. Video-Assisted thoracoscopic lobectomy for lung cancer. Ann Thorac Surg 2019; 107: 603-609. https://doi.org/10.1016/j.athoracsur.2018.07.088

CHAI T, LIN Y, KANG M, LIN J. Thoracotomy versus video-assisted thoracoscopic resection of lung cancer: A protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2019; 98: e14646. https://doi.org/10.1097/md.0000000000014646

CHAI T, LIN Y, SHEN Z, CHEN S, ZHANG Z, LIN W et al. Comparison between video-assisted thoracoscopic lung cancer resection and robot-assisted lung cancer resection: Protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2019; 98: e14790. https://doi.org/10.1097/md.0000000000014790

ZENG W, ZHANG W, ZHANG J, YOU G, MAO Y, XU J et al. Systematic review and meta-analysis of video-assisted thoracoscopic surgery segmentectomy versus lobectomy for stage I non-small cell lung cancer. World J Surg Oncol 2020; 18: 44. https://doi.org/10.1186/s12957-020-01814-x

LIM E, BATCHELOR T, SHACKCLOTH M, DUNNING J, MCGONIGLE N, BRUSH T et al. Study protocol for VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a UK multicentre randomised controlled trial with an internal pilot (the VIOLET study). BMJ Open 2019; 9: e029507. https://doi.org/10.1136/bmjopen-2019-029507

GHARAGOZLOO F, MEYER M, TEMPESTA B. Robotic Lobectomy: Experience with 638 consecutive cases. Surg Technol Int 2020 May;36:251-256.

O’SULLIVAN KE, KREADEN US, HEBERT AE, EATON D, REDMOND KC. A systematic review and meta-analysis of robotic versus open and video-assisted thoracoscopic surgery approaches for lobectomy. Interact Cardiovasc Thorac Surg 2019; 28: 526-534. https://doi.org/10.1093/icvts/ivy315

PERRONI G, VERONESI G. Robotic segmentectomy: indication and technique. J Thorac Dis 2020; 12: 3404-3410. https://doi.org/10.21037/jtd.2020.02.53

MEACCI E, NACHIRA D, ZANFRINI E, TRIUMBARI EKA, IAFFALDANO AG, CONGEDO MT et al. Uniportal VATS approach to sub-lobar anatomic resections: literature review and personal experience. J Thorac Dis 2020; 12: 3376-3389. https://doi.org/10.21037/jtd.2020.01.12

CALL S, OBIOLS C, RAMI-PORTA R. Present indications of surgical exploration of the mediastinum. J Thorac Dis 2018; 10 (Suppl 22): S2601- S2610. https://doi.org/10.21037/jtd.2018.03.183

SCHULLER HM. The impact of smoking and the influence of other factors on lung cancer. Expert Rev Respir Med 2019; 13: 761-769. https://doi.org/10.1080/17476348.2019.1645010

PARASCANDOLA M, XIAO L. Tobacco and the lung cancer epidemic in China. Transl lung cancer Res 2019; 8 (Suppl 1): S21-S30. https://doi.org/10.21037/tlcr.2019.03.12

STONE E, MARSHALL H. Tobacco and electronic nicotine delivery systems regulation. Transl lung cancer Res 2019; 8 (Suppl 1): S67-S76. https://doi.org/10.21037/tlcr.2019.03.13

ABERLE DR, DEMELLO S, BERG CD, BLACK WC, BREWER B, CHURCH TR et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med 2013; 369: 920-931. https://doi.org/10.1056/nejmoa1208962

ABERLE DR, ADAMS AM, BERG CD, BLACK WC, CLAPP JD, FAGERSTROM RM et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409. https://doi.org/10.1056/nejmoa1102873

DE KONING HJ, VAN DER AALST CM, DE JONG PA, SCHOLTEN ET, NACKAERTS K, HEUVELMANS MA et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med 2020; 382: 503-513. https://doi.org/10.1056/nejmoa1911793

SANCHEZ-SALCEDO P, WILSON DO, DE-TORRES JP, WEISSFELD JL, BERTO J, CAMPO A et al. Improving selection criteria for lung cancer screening: The potential role of emphysema. Am J Respir Crit Care Med 2015; 191. https://doi.org/10.1164/rccm.201410-1848oc

SEIJO LM, PELED N, AJONA D, BOERI M, FIELD JK, SOZZI G et al. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. J Thorac Oncol 2019; 14: 343-357. https://doi.org/10.1016/j.jtho.2018.11.023




Cómo citar

Montuenga, L., & Zulueta, J. (2020). Avances en el manejo del cáncer de pulmón. Anales Del Sistema Sanitario De Navarra, 43(2), 131–139. https://doi.org/10.23938/ASSN.0886